Reviews Climara Pro


No reviews yet.

Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009




Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009




Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009




Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009




Climara Pro Drug Description
Climara Pro®
(estradiol/levonorgestrel) Transdermal System

WARNINGS
Estrogens and progestins should not be used for the prevention of cardiovascular
disease or dementia. (See WARNINGS, Cardiovascular
disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of
treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders and Malignant neoplasms, Breast cancer.)
The WHI study reported increased risks of stroke and deep vein thrombosis in
postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with
oral conjugated estrogens (CE 0.625 mg) relative to placebo. (See Clinical
Studies and WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4 years of treatment with CE 0.625 mg combined with MPA
2.5 mg and during 5.2 years of treatment with CE 0.625 mg alone, relative to
placebo. It is unknown whether this finding applies to younger postmenopausal
women. (See Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

DRUG DESCRIPTION



What are the possible side effects of estradiol and levonorgestrel (Climara Pro)?

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of the following serious side effects:

signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
signs of a heart attack (crushing chest pain, left-arm numbness);
signs of a...
Read All Potential Side Effects for Climara Pro »




Climara Pro® (Estradiol/Levonorgestrel Transdermal System) is an adhesive-based
matrix transdermal patch designed to release both estradiol and levonorgestrel,
a progestational agent, continuously upon application to intact skin.
The 22 cm2 Climara Pro system contains 4.4 mg estradiol and 1.39
mg levonorgestrel and provides a nominal delivery rate (mg per day) of 0.045
estradiol and 0.015 levonorgestrel.
Estradiol USP has a molecular weight of 272.39 and the molecular formula is
C18H24O2.
Levonorgestrel USP has a molecular weight of 312.4 and a molecular formula
of C21H28O2.
The structural formulas for estradiol and levonorgestrel are:








The Climara Pro system comprises 3 layers. Proceeding from the visible surface
towards the surface attached to the skin, these layers are (1) a translucent
polyethylene backing film, (2) an acrylate adhesive matrix containing estradiol
and levonorgestrel, and (3) a protective liner of either siliconized or fluoropolymer
coated polyester film. The protective liner is attached to the adhesive surface
and must be removed before the system can be used.








The active components of the system are estradiol and levonorgestrel. The remaining
components of the system (acrylate copolymer adhesive and polyvinylpyrrolidone/vinyl
acetate copolymer) are pharmacologically inactive.Last reviewed on RxList: 2/19/2009





Other reviews about Climara Pro on wordpress

A Drug By Any Other Name
  by sdutchen
Viagra suggests vigor and virility and evokes the forceful flow of Niagara Falls. Zyrtec and Nexium feature fricatives that imply speed and advanced technology. Lipitor capitalizes on the […]


Premarin® (conjugated estrogens) Tablets, USP
  by kanlayanee
[caption id="" align="alignnone" width="288" caption="PREMARIN 0.3 MG TABLET"][/caption] Adult Min/Max Dose: 0.3mg/30.0mg Common Dosages by Indication: Atrophic Vaginitis associated with Menopause take 1 tablet (0.3 mg) po once daily take 1 tablet (0.3 […]


FDA Approved Bioidentical Hormones
  by bodylogicmd
We've mentioned that the FDA has approved over 20 bioidentical hormones and now want to share some of the hormones on that list, specifically those meant to treat […]


The Gory Details (oopherectomy & hysterectomy)
  by Teri Smieja
Out of all of the entries that I’ve written since I started this blog last March, the post that has gotten the most views (by a landslide!) is […]


3 Week Recovery Update
  by Teri Smieja
Tomorrow will be three weeks since my laparoscopic Hysterectomy & Bilateral Salpingo Oopherectomy – what a mouthful! This entry may only interest those who are wondering what to […]


Lookin Good...
  by brca1+
I went to my GYN for my annual on Friday and made out fine. She was up on all of my goings on because the Breast Specialist has […]


Americans Need Help Getting Meds- How to Get Free or Reduced Needed RX medications
  by paganmedia
Thanks to USA federal government incentives, pharmaceutical companies may provide free prescription medicines if : Sourced and Submitted: By Lady Paradise ~ With much appreciated thanks on this […]


Countdown is on...
  by brca1+
I'm going in for surgery (to put the right expander back in)  a week from today and I'm anxious to have it behind me. We're in the midst […]


The lady of the caravan was
  by fdouyjzbklx
In addition to the previous clatter, there were now sounds from the aircraft a thump and a low shuddery noise. It meant being a bad boy, being on […]


66:12 Thou hast caused men to ride
  by zjizgydqztqly
It leaned gloomily on its kickstand, bigger than the biggest of the others on display, dull where they were shiny, straight in places where the others were curved, […]



Other reviews about Climara Pro on web:

Home page for CLIMARA and CLIMARA PRO combined web site CLIMARA.COM: Home Page


Climara Pro (estradiol and levonorgestrel) treats menopause symptoms and helps prevent osteoporosis. Includes Climara Pro side effects, interactions and indications. Climara Pro Information from Drugs.com


Learn about the prescription medication Climara Pro (Estradiol, Levonorgestrel Transdermal), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Climara Pro (Estradiol, Levonorgestrel Transdermal) Drug ...


Accurate, FDA approved Climara Pro information for healthcare professionals and patients - brought to you by Drugs.com. Climara Pro Official FDA information, side effects and uses.


Find patient medical information for Climara Pro TD on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Climara Pro TD : Uses, Side Effects, Interactions, Pictures ...


Climara Pro is an estrogen and progestin hormone combination used to provide female hormone when the body no longer produces enough. Side effects and interactions are available at ... Climara Pro - drugstore.com. Low prices, side effects, interactions.


Climara Pro is a skin patch prescribed to treat menopausal symptoms and prevent osteoporosis. This eMedTV article describes this hormone replacement medication in more detail ... Climara Pro


(Redirected from Climara pro) ... Hormone replacement therapy (HRT) is a system of medical treatment for surgically ... Hormone replacement therapy (menopause) - Wikipedia, the free ...


Find user ratings and reviews for Climara Pro TD on WebMD including side effects and drug interactions, medication effectiveness, ease of use and satisfaction Climara Pro TD Reviews and User Ratings: Effectiveness, Ease of ...


Explanation of Natural Menopause, hormones, symptoms, CLIMARA PRO therapy Natural Menopause & Hormone Therapy : CLIMARA.COM





Featured Reviews

Reviews Oxiconazole

Oxistat Drug Description OXISTAT® (oxiconazole nitrate cream) Cream, 1%* OXISTAT® (oxiconazole nitrate lotion) Lotion, 1%* *Potency expressed as oxiconazole FOR TOPICAL DERMATOLOGIC USE ONLY- NOT FOR OPHTHALMIC OR INTRAVAGINAL...
Read More  |  Review This
Reviews Antivert

Antivert Drug Description ANTIVERT® (meclizine HCl) Tablets/12.5 mg ANTIVERT®/25 (meclizine HCl) Tablets/25 mg ANTIVERT®/50 (meclizine HCl) Tablets/50 mg DRUG DESCRIPTION What are the possible side effects of...
Read More  |  Review This
Reviews Tobi

Tobi Drug Description TOBI® (tobramycin) Inhalation Solution, USP Nebulizer Solution – For Inhalation Use Only DRUG DESCRIPTION What are the possible side effects of tobramycin (Tobi)? If you experience any of the following...
Read More  |  Review This
Reviews Calcipotriene and Betamethasone Dipropionate

Taclonex Drug Description TACLONEX® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) OINTMENT FOR TOPICAL USE ONLY. Not for Ophthalmic, Oral or Intravaginal Use. DRUG DESCRIPTION What are the possible side effects...
Read More  |  Review This
Reviews Gammagard

Gammagard Drug Description GAMMAGARD S/D Immune Globulin Intravenous (Human) SOLVENT DETERGENT TREATED DRUG DESCRIPTION What are the possible side effects of immune globulin? Get emergency medical help if you have any of these...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....